- Language: English
- 1050 Pages
- Published: December 2013
Regenerative Medicine Market in the US 2012-2016
- ID: 2617698
- July 2013
- Region: United States
- 48 Pages
The analysts forecast the Regenerative Medicine market in the US to grow at a CAGR of 15.83 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing number of degenerative diseases. The Regenerative Medicine market in the US has also been witnessing an increasing number of mergers and acquisitions. However, stringent regulatory approval processes could pose a challenge to the growth of this market.
The report, the Regenerative Medicine Market in the US 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years in the US. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this space include Baxter International Inc., Medtronic Inc., Stryker Corp., and Zimmer Holdings Inc.
The other vendors mentioned in the report are Advanced Cell Technology Inc., Athersys Inc., Arteriocyte Inc., Cytori Therapeutics Inc., CryoLife, Inc., Genzyme Corp., Geron Corp., Integra Life Sciences Holdings Corp., InVivo Therapeutics, Kensey Nash Corp., Kinetic Concepts Inc., NeoStem Inc., Osiris Therapeutics Inc., Osteotech Inc., and RTI Biologics Inc.
Key questions answered in this report:
- What will the market size be in 2016 and what will be the growth rate?
- What are key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by key vendors?
- What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details provided within the report. SHOW LESS READ MORE >
01. Executive Summary
02. List of Abbreviations
04. Market Research Methodology
Market Research Process
05. Scope of the Report
06. Market Landscape
06.1 Regenerative Medicine market in the US
Market Size and Forecast
06.2 Market Segmentation Based on Technology
06.3 Market Segmentation Based on Application
06.4 Five Forces Analysis
07. Vendor Landscape
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Key Vendor Analysis
14.1 Baxter International Inc.
14.2 Medtronic Inc.
14.3 Stryker Corp.
14.4 Zimmer Holdings Inc.
15. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Regenerative Medicine Market in the US 2012-2016 (US$ billion)
Exhibit 3: Market Segmentation by Technology
Exhibit 4: Market Segmentation by Technology 2012
Exhibit 5: Regenerative Medicine Market in the US Segmentation by Application
Exhibit 6: Regenerative Medicine Market Segmentation by Application2012
Exhibit 7: Business Segmentation of Baxter International Inc.
Exhibit 8: Business Segmentation of Medtronic Inc.
Exhibit 9: Business Segmentation of Stryker Corp.
Commenting on the report, an analyst from the team said: “There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market.”
According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D.
Further, the report states that the stringent regulatory approval process for Regenerative products is one of the major challenges faced by the market. The stringent approval processes inhibits the entry of new products into the market.
The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Advanced Cell Technology Inc., Athersys Inc., Cytori Therapeutics Inc., CryoLife Inc., Genzyme Corp., Integra Life Sciences Holdings Corp., Kensey Nash Corp., NeoStemInc., Osiris Therapeutics Inc., RTI Biologics Inc., and many more.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- Baxter International Inc.
- Medtronic Inc.
- Stryker Corp.
- Zimmer Holdings Inc.
- Advanced Cell Technology Inc.
- Athersys Inc.
- Arteriocyte Inc.
- Cytori Therapeutics Inc.
- Genzyme Corp.
- Geron Corp.
- Integra Life Sciences Holdings Corp.
- InVivo Therapeutics
- Kensey Nash Corp.
- Kinetic Concepts Inc.
- NeoStem Inc.
- Osiris Therapeutics Inc.
- Osteotech Inc.
- and RTI Biologics Inc.